drugset / Trial / NCT03443674
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered twice weekly for 2 weeks via IP bolus injection for the treatment of patients with peritoneal malignancies, including but not limited to peritoneal carcinomatosis, malignant ascites, pseudomyxoma peritonei, and peritoneal mesothelioma.
Timeline
- Start
- 2018-06-18
- Primary completion
- 2021-05-30
- Completion
- 2021-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCB-313 | Protein / enzyme biologic | 10 mg | Other |
| Subject | SCB-313 | Protein / enzyme biologic | 20 mg | Other |
| Subject | SCB-313 | Protein / enzyme biologic | 40 mg | Other |
| Subject | SCB-313 | Protein / enzyme biologic | 80 mg | Other |
| Subject | SCB-313 | Protein / enzyme biologic | 160 mg | Other |